Closing Perspectives and Future Directions in Multiple Myeloma Care

In this final episode, experts offer closing reflections on the rapid evolution of multiple myeloma treatment and the growing role of bispecific antibodies. Panelists emphasize that the field is moving toward earlier use of immunotherapies, improved sequencing strategies, and stronger integration between academic and community practices. They highlight how bispecifics, CAR T-cell therapy, and antibody drug conjugates continue to reshape expectations for response and survival, particularly as real world data confirm efficacy in broader patient populations. Experts underscore the need for ongoing education, streamlined operational approaches, and robust toxicity management to ensure safe expansion of these therapies. They also stress the importance of equitable access so that innovations benefit patients across diverse geographic and clinical settings. The conversation concludes with optimism that continued collaboration, thoughtful trial design, and real world evidence will drive progress toward more durable disease control in multiple myeloma.